Combination of cisplatin, epirubicin, and cyclophosphamide (PEC regimen) in advanced or recurrent endometrial cancer: A retrospective clinical study

The combination of cisplatin (50 mg/m(2)) epirubicin (60 mg/m(2)), and cycl ophosphamide (600 mg/m(2)) (PEC regimen) was given every 4 weeks to 19 pati ents with advanced (n.2) or recurrent (n.17) endometrial cancer. The median number of cycles delivered to each patient was 5 (range, 2-8). All patient s were evaluable for toxicity and 16 for response. Two (12.5%) patients exp erienced a complete response and 5 (31.2%) had a partial response, for an o verall objective response rare of 43.7%. The median duration of objective r esponse was 10 months (range, 3-28 months). Median survival was 10 months ( range, 3-68+ months) in the whole series. According to response to chemothe rapy, median survival was 12 months (range, 3-68+ months) for responders an d 9 months (range, 6-17 months) for nonresponders. Hematologic toxicity was relatively frequent but it could be easily managed, and significant nonhem atologic toxicities were not found except for nausea and vomiting. In concl usion, PEC regimen has a good activity in advanced or recurrent endometrial cancer, but the short duration of responses limits the impact of the treat ment on survival time.